インサイト

Growing demand for both small-molecule generics and biologic APIs is driving unprecedented investment in manufacturing capacity across Asia, Europe, and North America.

The FDA has announced a modernized inspection framework that prioritizes risk-based assessments, potentially reducing routine inspection frequency for high-compliance CDMOs.

Major capacity expansions across India, South Korea, and Southeast Asia are transforming the region into a global hub for contract pharmaceutical manufacturing.

Regulatory agencies are beginning to accept AI-generated evidence for drug repurposing applications, opening a faster and cheaper pathway to new treatments.

The World Health Organization urges member states to adopt standardized frameworks for medicine pricing disclosure to improve market access globally.

Pfizer announces a $400M investment to expand active pharmaceutical ingredient production capabilities at its Singapore facility.

New industry forecasts project the global pharmaceutical market will surpass $1.9 trillion by 2027, driven by biologics growth and expanding emerging markets.

The US FDA has issued new draft guidance clarifying regulatory expectations for continuous manufacturing processes in drug substance production.

An in-depth look at how biosimilar adoption is reshaping pharmaceutical pricing, supply chains, and competitive strategies across major markets.

The European Medicines Agency has published revised GMP guidelines for ATMPs including gene therapies, cell therapies, and tissue-engineered products.

Asia-Pacific CDMO capacity is expanding rapidly. We analyze where the highest-value opportunities lie for pharma companies seeking manufacturing partners.

A practical overview of how pharmaceutical manufacturers are implementing ICH Q12 lifecycle management principles into their post-approval change management workflows.

A comprehensive analysis of supply chain vulnerabilities, risk mitigation strategies, and technology adoption trends across global pharmaceutical supply networks.